ALEC
HealthcareAlector, Inc.
$2.19-0.04 (-2.02%)
Prev Close
$2.23
Open
$2.24
High
$2.33
Low
$2.13
Volume
513.3K
Market Cap
$241.1M
P/E
—
Div Yield
—
Over the past 12 months, insider activity at Alector, Inc. (ALEC) has been exclusively selling, with 0 insider purchases totaling $0.00 and 19 insider sales totaling $901.0K. The most recent insider transaction was by Wong-Sarad Grace (officer: Principal Accounting Officer), who sold $2.6K worth of shares on Mar 12, 2026. Alector, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $241.1M.
Buys (12M)
0
$0.00
Sells (12M)
19
$901.0K
Net Activity
Net Seller
$901.0K
Active Insiders
7
last 12 mo
ALEC Price Chart
ALEC Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 12, 2026↗ | Wong-Sarad Grace | officer: Principal Accounting Officer | Sell | 1,000 | $2.65 | $2.6K | 106,465 |
| Mar 3, 2026↗ | Berkley Neil Lindsay | officer: CFO & Chief Business Officer | Sell | 29,649 | $2.12 | $63.0K | 344,660 |
| Mar 3, 2026↗ | Rosenthal Arnon | director, officer: Chief Executive Officer | Sell | 81,864 | $2.12 | $173.8K | 2,338,180 |
| Mar 3, 2026↗ | Wong-Sarad Grace | officer: Principal Accounting Officer | Sell | 14,805 | $2.10 | $31.2K | 110,832 |
| Feb 26, 2026↗ | Wong-Sarad Grace | officer: Principal Accounting Officer | Sell | 4,079 | $2.50 | $10.2K | 118,903 |
| Dec 5, 2025↗ | Wong-Sarad Grace | Principal Accounting Officer | Sell | 4,753 | $1.21 | $5.8K | 0 |
| Dec 3, 2025↗ | Berkley Neil Lindsay | Chief Bus Ofcr & Interim CFO | Sell | 37,261 | $1.12 | $41.7K | 0 |
| Dec 3, 2025↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 41,687 | $1.12 | $46.7K | 0 |
| Dec 3, 2025↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 104,347 | $1.12 | $116.8K | 0 |
| Dec 3, 2025↗ | Wong-Sarad Grace | Principal Accounting Officer | Sell | 8,056 | $1.12 | $9.0K | 0 |
| Sep 2, 2025↗ | Berkley Neil Lindsay | Principal Financial Officer | Sell | 15,842 | $2.50 | $39.6K | 0 |
| Sep 2, 2025↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 23,638 | $2.50 | $59.0K | 0 |
| Sep 2, 2025↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 51,562 | $2.50 | $128.7K | 0 |
| Sep 2, 2025↗ | Wong-Sarad Grace | Principal Accounting Officer | Sell | 5,910 | $2.50 | $14.8K | 0 |
| Aug 26, 2025↗ | Hammond Paula | Director | Sell | 14,000 | $2.36 | $33.0K | 0 |
| Jun 20, 2025↗ | Yaffe Kristine | Director | Sell | 1,000 | $1.44 | $1.4K | 0 |
| Jun 2, 2025↗ | GRASSO MARC | Chief Financial Officer | Sell | 16,488 | $1.34 | $22.1K | 0 |
| Jun 2, 2025↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 23,890 | $1.34 | $32.0K | 0 |
| Jun 2, 2025↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 52,087 | $1.34 | $69.7K | 0 |
| Mar 3, 2025↗ | GRASSO MARC | Chief Financial Officer | Sell | 18,091 | $1.47 | $26.5K | 0 |
| Mar 3, 2025↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 29,073 | $1.47 | $42.7K | 0 |
| Mar 3, 2025↗ | Romano Gary | Chief Medical Officer | Sell | 16,306 | $1.47 | $23.9K | 0 |
| Mar 3, 2025↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 40,330 | $1.47 | $59.2K | 0 |
| Dec 2, 2024↗ | GRASSO MARC | Chief Financial Officer | Sell | 16,489 | $2.52 | $41.5K | 0 |
| Dec 2, 2024↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 26,500 | $2.52 | $66.8K | 0 |
| Dec 2, 2024↗ | Romano Gary | Chief Medical Officer | Sell | 14,892 | $2.52 | $37.5K | 0 |
| Dec 2, 2024↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 52,172 | $2.52 | $131.4K | 0 |
| Sep 3, 2024↗ | GRASSO MARC | Chief Financial Officer | Sell | 7,297 | $4.88 | $35.6K | 0 |
| Sep 3, 2024↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 13,926 | $4.88 | $68.0K | 0 |
| Sep 3, 2024↗ | Romano Gary | Chief Medical Officer | Sell | 8,478 | $4.88 | $41.4K | 0 |
| Sep 3, 2024↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 26,499 | $4.88 | $129.4K | 0 |
| Aug 22, 2024↗ | SCHELLER RICHARD H | Director | Sell | 44,250 | $5.16 | $228.4K | 0 |
| Aug 12, 2024↗ | Hammond Paula | Director | Sell | 10,500 | $5.06 | $53.2K | 0 |
| Aug 12, 2024↗ | Yaffe Kristine | Director | Sell | 5,000 | $5.06 | $25.3K | 0 |
| Jun 3, 2024↗ | GRASSO MARC | Chief Financial Officer | Sell | 6,920 | $4.80 | $33.2K | 0 |
| Jun 3, 2024↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 13,206 | $4.80 | $63.4K | 0 |
| Jun 3, 2024↗ | Romano Gary | Chief Medical Officer | Sell | 8,040 | $4.80 | $38.6K | 0 |
| Jun 3, 2024↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 25,135 | $4.80 | $120.6K | 0 |
| Mar 4, 2024↗ | GRASSO MARC | Chief Financial Officer | Sell | 5,716 | $6.92 | $39.6K | 0 |
| Mar 4, 2024↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 10,169 | $6.92 | $70.4K | 0 |
| Mar 4, 2024↗ | Romano Gary | Chief Medical Officer | Sell | 6,001 | $6.92 | $41.6K | 0 |
| Mar 4, 2024↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 18,837 | $6.92 | $130.4K | 0 |
| Dec 4, 2023↗ | GRASSO MARC | Chief Financial Officer | Sell | 4,574 | $5.56 | $25.4K | 0 |
| Dec 4, 2023↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 12,519 | $5.56 | $69.6K | 0 |
| Dec 4, 2023↗ | Romano Gary | Chief Medical Officer | Sell | 5,035 | $5.56 | $28.0K | 0 |
| Dec 4, 2023↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 23,831 | $5.56 | $132.5K | 0 |
| Sep 11, 2023↗ | MCGUIRE TERRANCE | Director | Sell | 500,000 | $6.00 | $3.00M | 0 |
| Sep 5, 2023↗ | GRASSO MARC | Chief Financial Officer | Sell | 1,114 | $5.19 | $5.8K | 0 |
| Sep 5, 2023↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 6,214 | $5.19 | $32.3K | 0 |
| Sep 5, 2023↗ | Romano Gary | Chief Medical Officer | Sell | 2,771 | $5.19 | $14.4K | 0 |
| Sep 5, 2023↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 5,647 | $5.19 | $29.3K | 0 |
| Jun 2, 2023↗ | GRASSO MARC | Chief Financial Officer | Sell | 1,050 | $6.90 | $7.2K | 0 |
| Jun 2, 2023↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 4,092 | $6.90 | $28.2K | 0 |
| Jun 2, 2023↗ | Romano Gary | Chief Medical Officer | Sell | 2,617 | $6.90 | $18.1K | 0 |
| Jun 2, 2023↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 5,255 | $6.90 | $36.3K | 0 |
| Mar 3, 2023↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 15,186 | $6.22 | $94.4K | 0 |
| Mar 2, 2023↗ | GRASSO MARC | Chief Financial Officer | Sell | 1,291 | $8.32 | $10.7K | 0 |
| Mar 2, 2023↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 10,124 | $8.32 | $84.2K | 0 |
| Mar 2, 2023↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 5,849 | $8.32 | $48.7K | 0 |
| Dec 2, 2022↗ | Romano Gary | Chief Medical Officer | Sell | 5,383 | $8.47 | $45.6K | 0 |
| Sep 2, 2022↗ | King Robert | Chief Development Officer | Sell | 176 | $10.62 | $1.9K | 0 |
| Sep 2, 2022↗ | Romano Gary | Chief Medical Officer | Sell | 2,177 | $10.62 | $23.1K | 0 |
| Jun 2, 2022↗ | King Robert | Chief Development Officer | Sell | 177 | $8.71 | $1.5K | 0 |
| Mar 1, 2022↗ | King Robert | Chief Development Officer | Sell | 287 | $15.57 | $4.5K | 0 |
| Dec 10, 2021↗ | SULIMAN SHEHNAAZ | President and COO | Sell | 150,000 | $21.50 | $3.23M | 0 |
| Dec 8, 2021↗ | SULIMAN SHEHNAAZ | President and COO | Sell | 150,000 | $22.81 | $3.42M | 0 |
| Dec 1, 2021↗ | King Robert | Chief Development Officer | Sell | 250 | $20.09 | $5.0K | 0 |
| Nov 10, 2021↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 110,000 | $25.00 | $2.75M | 0 |
| Nov 8, 2021↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 200,000 | $25.00 | $5.00M | 0 |
| Nov 4, 2021↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 200,000 | $25.00 | $5.00M | 0 |
| Sep 22, 2021↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 109,625 | $25.31 | $2.77M | 0 |
| Sep 20, 2021↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 200,000 | $25.96 | $5.19M | 0 |
| Aug 9, 2021↗ | Paul Robert | Chief Medical Officer | Sell | 22,950 | $27.18 | $623.8K | 0 |
| Jul 6, 2021↗ | Paul Robert | Chief Medical Officer | Sell | 59,749 | $38.00 | $2.27M | 0 |
| Jul 2, 2021↗ | King Robert | Chief Development Officer | Sell | 60,000 | $31.14 | $1.87M | 0 |
| Jul 2, 2021↗ | SCHELLER RICHARD H | Director | Sell | 66,241 | $28.20 | $1.87M | 0 |
| Jul 2, 2021↗ | Yu Calvin | Vice President, Finance | Sell | 114,174 | $32.80 | $3.74M | 0 |
| Jul 1, 2021↗ | Paul Robert | Chief Medical Officer | Sell | 56,726 | $26.94 | $1.53M | 0 |
| Jun 15, 2021↗ | Paul Robert | Chief Medical Officer | Sell | 34,600 | $22.08 | $764.0K | 0 |
| Jun 8, 2021↗ | Paul Robert | Chief Medical Officer | Sell | 19,175 | $19.18 | $367.7K | 0 |
| Jun 2, 2021↗ | Yu Calvin | Vice President, Finance | Sell | 1,844 | $17.77 | $32.8K | 0 |
| May 21, 2021↗ | Paul Robert | Chief Medical Officer | Sell | 14,975 | $18.14 | $271.7K | 0 |
| May 18, 2021↗ | Paul Robert | Chief Medical Officer | Sell | 4,200 | $18.04 | $75.8K | 0 |
| Apr 7, 2021↗ | Paul Robert | Chief Medical Officer | Sell | 22,300 | $19.20 | $428.1K | 0 |
| Mar 22, 2021↗ | Paul Robert | Chief Medical Officer | Sell | 43,800 | $22.74 | $995.9K | 0 |
| Mar 9, 2021↗ | Paul Robert | Chief Medical Officer | Sell | 19,175 | $18.12 | $347.4K | 0 |
ALEC Insider Buying Activity
The following table shows recent insider purchases of Alector, Inc. (ALEC) stock reported via SEC Form 4 filings.
No insider buying activity found for ALEC in the last 12 months.
ALEC Insider Selling Activity
The following table shows recent insider sales of Alector, Inc. (ALEC) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 12, 2026↗ | Wong-Sarad Grace | officer: Principal Accounting Officer | Sell | 1,000 | $2.65 | $2.6K | 106,465 |
| Mar 3, 2026↗ | Berkley Neil Lindsay | officer: CFO & Chief Business Officer | Sell | 29,649 | $2.12 | $63.0K | 344,660 |
| Mar 3, 2026↗ | Rosenthal Arnon | director, officer: Chief Executive Officer | Sell | 81,864 | $2.12 | $173.8K | 2,338,180 |
| Mar 3, 2026↗ | Wong-Sarad Grace | officer: Principal Accounting Officer | Sell | 14,805 | $2.10 | $31.2K | 110,832 |
| Feb 26, 2026↗ | Wong-Sarad Grace | officer: Principal Accounting Officer | Sell | 4,079 | $2.50 | $10.2K | 118,903 |
| Dec 5, 2025↗ | Wong-Sarad Grace | Principal Accounting Officer | Sell | 4,753 | $1.21 | $5.8K | 0 |
| Dec 3, 2025↗ | Berkley Neil Lindsay | Chief Bus Ofcr & Interim CFO | Sell | 37,261 | $1.12 | $41.7K | 0 |
| Dec 3, 2025↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 41,687 | $1.12 | $46.7K | 0 |
| Dec 3, 2025↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 104,347 | $1.12 | $116.8K | 0 |
| Dec 3, 2025↗ | Wong-Sarad Grace | Principal Accounting Officer | Sell | 8,056 | $1.12 | $9.0K | 0 |
| Sep 2, 2025↗ | Berkley Neil Lindsay | Principal Financial Officer | Sell | 15,842 | $2.50 | $39.6K | 0 |
| Sep 2, 2025↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 23,638 | $2.50 | $59.0K | 0 |
| Sep 2, 2025↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 51,562 | $2.50 | $128.7K | 0 |
| Sep 2, 2025↗ | Wong-Sarad Grace | Principal Accounting Officer | Sell | 5,910 | $2.50 | $14.8K | 0 |
| Aug 26, 2025↗ | Hammond Paula | Director | Sell | 14,000 | $2.36 | $33.0K | 0 |
| Jun 20, 2025↗ | Yaffe Kristine | Director | Sell | 1,000 | $1.44 | $1.4K | 0 |
| Jun 2, 2025↗ | GRASSO MARC | Chief Financial Officer | Sell | 16,488 | $1.34 | $22.1K | 0 |
| Jun 2, 2025↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 23,890 | $1.34 | $32.0K | 0 |
| Jun 2, 2025↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 52,087 | $1.34 | $69.7K | 0 |
| Mar 3, 2025↗ | GRASSO MARC | Chief Financial Officer | Sell | 18,091 | $1.47 | $26.5K | 0 |
| Mar 3, 2025↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 29,073 | $1.47 | $42.7K | 0 |
| Mar 3, 2025↗ | Romano Gary | Chief Medical Officer | Sell | 16,306 | $1.47 | $23.9K | 0 |
| Mar 3, 2025↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 40,330 | $1.47 | $59.2K | 0 |
| Dec 2, 2024↗ | GRASSO MARC | Chief Financial Officer | Sell | 16,489 | $2.52 | $41.5K | 0 |
| Dec 2, 2024↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 26,500 | $2.52 | $66.8K | 0 |
| Dec 2, 2024↗ | Romano Gary | Chief Medical Officer | Sell | 14,892 | $2.52 | $37.5K | 0 |
| Dec 2, 2024↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 52,172 | $2.52 | $131.4K | 0 |
| Sep 3, 2024↗ | GRASSO MARC | Chief Financial Officer | Sell | 7,297 | $4.88 | $35.6K | 0 |
| Sep 3, 2024↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 13,926 | $4.88 | $68.0K | 0 |
| Sep 3, 2024↗ | Romano Gary | Chief Medical Officer | Sell | 8,478 | $4.88 | $41.4K | 0 |
| Sep 3, 2024↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 26,499 | $4.88 | $129.4K | 0 |
| Aug 22, 2024↗ | SCHELLER RICHARD H | Director | Sell | 44,250 | $5.16 | $228.4K | 0 |
| Aug 12, 2024↗ | Hammond Paula | Director | Sell | 10,500 | $5.06 | $53.2K | 0 |
| Aug 12, 2024↗ | Yaffe Kristine | Director | Sell | 5,000 | $5.06 | $25.3K | 0 |
| Jun 3, 2024↗ | GRASSO MARC | Chief Financial Officer | Sell | 6,920 | $4.80 | $33.2K | 0 |
| Jun 3, 2024↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 13,206 | $4.80 | $63.4K | 0 |
| Jun 3, 2024↗ | Romano Gary | Chief Medical Officer | Sell | 8,040 | $4.80 | $38.6K | 0 |
| Jun 3, 2024↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 25,135 | $4.80 | $120.6K | 0 |
| Mar 4, 2024↗ | GRASSO MARC | Chief Financial Officer | Sell | 5,716 | $6.92 | $39.6K | 0 |
| Mar 4, 2024↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 10,169 | $6.92 | $70.4K | 0 |
| Mar 4, 2024↗ | Romano Gary | Chief Medical Officer | Sell | 6,001 | $6.92 | $41.6K | 0 |
| Mar 4, 2024↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 18,837 | $6.92 | $130.4K | 0 |
| Dec 4, 2023↗ | GRASSO MARC | Chief Financial Officer | Sell | 4,574 | $5.56 | $25.4K | 0 |
| Dec 4, 2023↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 12,519 | $5.56 | $69.6K | 0 |
| Dec 4, 2023↗ | Romano Gary | Chief Medical Officer | Sell | 5,035 | $5.56 | $28.0K | 0 |
| Dec 4, 2023↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 23,831 | $5.56 | $132.5K | 0 |
| Sep 11, 2023↗ | MCGUIRE TERRANCE | Director | Sell | 500,000 | $6.00 | $3.00M | 0 |
| Sep 5, 2023↗ | GRASSO MARC | Chief Financial Officer | Sell | 1,114 | $5.19 | $5.8K | 0 |
| Sep 5, 2023↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 6,214 | $5.19 | $32.3K | 0 |
| Sep 5, 2023↗ | Romano Gary | Chief Medical Officer | Sell | 2,771 | $5.19 | $14.4K | 0 |
| Sep 5, 2023↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 5,647 | $5.19 | $29.3K | 0 |
| Jun 2, 2023↗ | GRASSO MARC | Chief Financial Officer | Sell | 1,050 | $6.90 | $7.2K | 0 |
| Jun 2, 2023↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 4,092 | $6.90 | $28.2K | 0 |
| Jun 2, 2023↗ | Romano Gary | Chief Medical Officer | Sell | 2,617 | $6.90 | $18.1K | 0 |
| Jun 2, 2023↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 5,255 | $6.90 | $36.3K | 0 |
| Mar 3, 2023↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 15,186 | $6.22 | $94.4K | 0 |
| Mar 2, 2023↗ | GRASSO MARC | Chief Financial Officer | Sell | 1,291 | $8.32 | $10.7K | 0 |
| Mar 2, 2023↗ | Kenkare-Mitra Sara | President and Head of R&D | Sell | 10,124 | $8.32 | $84.2K | 0 |
| Mar 2, 2023↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 5,849 | $8.32 | $48.7K | 0 |
| Dec 2, 2022↗ | Romano Gary | Chief Medical Officer | Sell | 5,383 | $8.47 | $45.6K | 0 |
| Sep 2, 2022↗ | King Robert | Chief Development Officer | Sell | 176 | $10.62 | $1.9K | 0 |
| Sep 2, 2022↗ | Romano Gary | Chief Medical Officer | Sell | 2,177 | $10.62 | $23.1K | 0 |
| Jun 2, 2022↗ | King Robert | Chief Development Officer | Sell | 177 | $8.71 | $1.5K | 0 |
| Mar 1, 2022↗ | King Robert | Chief Development Officer | Sell | 287 | $15.57 | $4.5K | 0 |
| Dec 10, 2021↗ | SULIMAN SHEHNAAZ | President and COO | Sell | 150,000 | $21.50 | $3.23M | 0 |
| Dec 8, 2021↗ | SULIMAN SHEHNAAZ | President and COO | Sell | 150,000 | $22.81 | $3.42M | 0 |
| Dec 1, 2021↗ | King Robert | Chief Development Officer | Sell | 250 | $20.09 | $5.0K | 0 |
| Nov 10, 2021↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 110,000 | $25.00 | $2.75M | 0 |
| Nov 8, 2021↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 200,000 | $25.00 | $5.00M | 0 |
| Nov 4, 2021↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 200,000 | $25.00 | $5.00M | 0 |
| Sep 22, 2021↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 109,625 | $25.31 | $2.77M | 0 |
| Sep 20, 2021↗ | Rosenthal Arnon | Chief Executive Officer | Sell | 200,000 | $25.96 | $5.19M | 0 |
| Aug 9, 2021↗ | Paul Robert | Chief Medical Officer | Sell | 22,950 | $27.18 | $623.8K | 0 |
| Jul 6, 2021↗ | Paul Robert | Chief Medical Officer | Sell | 59,749 | $38.00 | $2.27M | 0 |
| Jul 2, 2021↗ | King Robert | Chief Development Officer | Sell | 60,000 | $31.14 | $1.87M | 0 |
| Jul 2, 2021↗ | SCHELLER RICHARD H | Director | Sell | 66,241 | $28.20 | $1.87M | 0 |
| Jul 2, 2021↗ | Yu Calvin | Vice President, Finance | Sell | 114,174 | $32.80 | $3.74M | 0 |
| Jul 1, 2021↗ | Paul Robert | Chief Medical Officer | Sell | 56,726 | $26.94 | $1.53M | 0 |
| Jun 15, 2021↗ | Paul Robert | Chief Medical Officer | Sell | 34,600 | $22.08 | $764.0K | 0 |
| Jun 8, 2021↗ | Paul Robert | Chief Medical Officer | Sell | 19,175 | $19.18 | $367.7K | 0 |
| Jun 2, 2021↗ | Yu Calvin | Vice President, Finance | Sell | 1,844 | $17.77 | $32.8K | 0 |
| May 21, 2021↗ | Paul Robert | Chief Medical Officer | Sell | 14,975 | $18.14 | $271.7K | 0 |
| May 18, 2021↗ | Paul Robert | Chief Medical Officer | Sell | 4,200 | $18.04 | $75.8K | 0 |
| Apr 7, 2021↗ | Paul Robert | Chief Medical Officer | Sell | 22,300 | $19.20 | $428.1K | 0 |
| Mar 22, 2021↗ | Paul Robert | Chief Medical Officer | Sell | 43,800 | $22.74 | $995.9K | 0 |
| Mar 9, 2021↗ | Paul Robert | Chief Medical Officer | Sell | 19,175 | $18.12 | $347.4K | 0 |
ALEC Insiders
Similar Stocks to ALEC
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$538.00+0.97%
$21.50B
INCY
Incyte Corporation
$92.25+0.27%
$20.10B
RVMD
Revolution Medicines, Inc.
$95.44+0.39%
$20.10B
MRNA
Moderna, Inc.
$52.38-1.89%
$19.96B